Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316741 | 1.00 | GAA (0.38) | GAAHIF1ALMNAKMT2AMEN1 | |
| SCHEMBL5569888 | 0.71 | KCNN4 (0.41) | GAALMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL1315351 | 0.69 | MEN1 (0.46) | GAAKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL304619 | 0.69 | MEN1 (0.46) | GAAKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL1758987 | 0.69 | MEN1 (0.46) | GAAKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL305198 | 0.69 | MEN1 (0.46) | GAAKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL580033 | 0.68 | OPRM1 (0.39) | ALDH1A1OPRK1CYP1A2CYP2C9MAPK1 | |
| SCHEMBL305263 | 0.68 | OPRM1 (0.39) | ALDH1A1OPRK1CYP1A2CYP2C9MAPK1 | |
| SCHEMBL305262 | 0.68 | OPRM1 (0.39) | ALDH1A1OPRK1CYP1A2CYP2C9MAPK1 | |
| SCHEMBL304095 | 0.67 | OPRL1 (0.53) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2049114-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8492553-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120328570-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-27 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328570-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | GAA 223/4885HIF1A 4316/4885LMNA 3159/4885 |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | GAA 223/4885HIF1A 4316/4885LMNA 3159/4885 |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | GAA 223/4885HIF1A 4316/4885LMNA 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.